Karolinska Development
An investment company that finances and supports innovative life science ventures.
KDEV | ST
Overview
Corporate Details
- ISIN(s):
- SE0002190850 (+1 more)
- LEI:
- 54930011ZA52NKO5W681
- Country:
- Sweden
- Address:
- Nanna Svartz väg 6A, 171 65 Solna
Description
Karolinska Development is an investment company specializing in the life sciences sector. It identifies, finances, and supports the creation and growth of companies developing innovative medical technologies and pharmaceuticals. The firm manages a diversified portfolio of biotechnology and medtech ventures, often originating from academic research, with the goal of developing ground-breaking treatments for severe diseases. Karolinska Development leverages its team's expertise in research, development, and commercialization to guide its portfolio companies, providing both capital and strategic support to advance innovations toward the market.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2012-11-22 08:28 | Swedish | 1.1 MB | |||
| 2012-11-22 08:28 | English | 1.1 MB | |||
| 2012-09-28 15:39 |
Purchase of own shares to cover social security fees related to incentive progr…
|
English | 99.1 KB | ||
| 2012-09-28 15:39 |
Återköp av egna aktier för att täcka sociala avgifter kopplade till incitaments…
|
Swedish | 98.3 KB | ||
| 2012-09-18 07:59 |
Aprea meddelar positiva data från en klinisk fas I/II-studie med APR-246 på pat…
|
Swedish | 112.8 KB | ||
| 2012-09-18 07:59 |
Aprea announces positive data from a clinical Phase I/II study with APR-246 in …
|
English | 113.5 KB | ||
| 2012-09-11 07:59 |
Pergamum meddelar att första patienten har doserats med potentiellt nytt läkeme…
|
Swedish | 113.5 KB | ||
| 2012-09-11 07:59 |
Pergamum announces that first patient has been dosed with potential new treatme…
|
English | 115.5 KB | ||
| 2012-08-23 08:29 | Swedish | 448.3 KB | |||
| 2012-08-23 08:29 | English | 472.1 KB | |||
| 2012-07-10 08:12 |
Pergamum reports top line Phase II-data from the clinical trial for prevention …
|
English | 309.4 KB | ||
| 2012-07-10 08:12 |
Pergamum rapporterar första fas II-data från den kliniska studien för förebygga…
|
Swedish | 298.5 KB | ||
| 2012-06-13 08:30 |
Karolinska Development genomför aktiebyte med Industrifonden
|
Swedish | 106.9 KB | ||
| 2012-06-13 08:30 |
Karolinska Development arranges a share ownership exchange with Industrifonden
|
English | 108.9 KB | ||
| 2012-06-12 08:29 |
Pharmanest initiates Phase II study of SHACT
|
English | 115.1 KB |
Automate Your Workflow. Get a real-time feed of all Karolinska Development filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Karolinska Development
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Karolinska Development via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-05-04 | Johan Dighed | Other | Buy | 35,000 | 56,350.00 SEK |
| 2023-03-27 | Johan Dighed | Other | Buy | 50,000 | 89,000.00 SEK |
| 2023-02-17 | Hans Christopher Karl Osvald Perbandt Toll | Other | Buy | 35,000 | 72,100.00 SEK |
| 2022-12-19 | Johan Dighed | Other | Buy | 50,000 | 83,500.00 SEK |
| 2022-09-30 | Johan Dighed | Other | Buy | 40,187 | 72,336.60 SEK |
| 2020-06-26 | Hans Lennart Rudolf Wigzell | Other | Buy | 9,014 | 25,780.04 SEK |
| 2020-06-26 | Hans Lennart Rudolf Wigzell | Other | Buy | 5,000 | 14,350.00 SEK |
| 2020-06-24 | Hans Lennart Rudolf Wigzell | Other | Buy | 9,276 | 26,529.36 SEK |
| 2020-06-24 | Hans Lennart Rudolf Wigzell | Other | Buy | 4,645 | 13,331.15 SEK |
| 2020-06-23 | Hans Lennart Rudolf Wigzell | Other | Buy | 39,702 | 111,562.62 SEK |
Peer Companies
